Differential Diagnosis of Tuberculosis: A Comprehensive Guide for Clinicians

Introduction

Tuberculosis (TB), a disease known since antiquity and formally identified by Robert Koch in 1882, remains a global health crisis. Despite advancements in diagnostics and treatment, TB is still a leading cause of death from infectious agents worldwide, surpassing even HIV/AIDS in mortality. Approximately one-third of the global population is infected with Mycobacterium tuberculosis, the causative bacterium, with an estimated ten million new cases occurring annually. This enduring pandemic underscores the critical need for clinicians to maintain a high index of suspicion and proficiency in diagnosing and managing TB.

Pulmonary tuberculosis, the focus of this discussion, primarily affects the lungs, accounting for up to 87% of TB cases. However, TB is a systemic disease and can involve virtually any organ in the body. The disease disproportionately affects vulnerable populations, including those living in crowded environments, immigrants from high-burden countries, immunocompromised individuals, and healthcare workers. While global incidence rates have been gradually declining, TB remains a significant public health challenge, particularly in regions like Sub-Saharan Africa, contributing to an estimated 1.5 million deaths each year. Furthermore, pulmonary tuberculosis can lead to long-term lung function impairment, highlighting the importance of timely and accurate diagnosis.

A cornerstone of effective TB management is accurate diagnosis, which includes considering a broad differential diagnosis. Pulmonary tuberculosis can mimic a variety of other respiratory conditions, ranging from benign infections to malignancies. This article provides a comprehensive guide to the Differential Diagnosis Of Tuberculosis, equipping clinicians with the knowledge to effectively distinguish TB from other conditions with similar clinical and radiological presentations. By understanding the nuances of each potential diagnosis, clinicians can ensure timely and appropriate management, ultimately improving patient outcomes and contributing to global TB control efforts.

Etiology of Tuberculosis

Tuberculosis is caused by Mycobacterium tuberculosis, a bacterium belonging to the Mycobacterium genus, which encompasses over 170 species. M. tuberculosis is a slow-growing, aerobic, non-motile bacillus characterized by a complex, lipid-rich cell wall. This bacterium is classified as gram-positive, although it stains poorly with Gram stain due to its unique cell wall structure. The cell wall’s high content of mycolic acids and other lipids contributes to its acid-fast property, a key characteristic used in diagnostic staining techniques like Ziehl-Neelsen staining.

The M. tuberculosis cell wall is crucial to its pathogenesis, providing protection and contributing to its virulence. It is composed of peptidoglycans, complex lipids, and an outer capsule. These components facilitate the bacterium’s survival within macrophages, the primary immune cells that attempt to engulf and destroy pathogens. M. tuberculosis is a facultative intracellular bacterium, meaning it can survive and replicate both inside and outside of host cells. It inhibits macrophage function, allowing it to proliferate within these cells, eventually leading to macrophage death and the release of bacilli into the alveolar spaces of the lungs. This intracellular survival mechanism is a key factor in the bacterium’s ability to establish chronic infection and evade the host’s immune system. The slow growth rate of M. tuberculosis, with a generation time of up to 24 hours, also contributes to the chronic nature of the disease and poses challenges for rapid diagnosis.

Epidemiology of Tuberculosis

Tuberculosis is a globally reportable disease, allowing for systematic monitoring and epidemiological tracking. While TB incidence had been declining, the HIV epidemic reversed this trend, highlighting the synergistic relationship between these two diseases. TB is now a leading cause of morbidity and mortality worldwide, especially among individuals with HIV co-infection. It is estimated that approximately 1.7 billion people globally are infected with M. tuberculosis.

The World Health Organization (WHO) estimated 10 million new TB cases in 2017, with India and China bearing a significant burden of TB-related deaths. Poverty is a major driver of TB incidence, with low-income countries experiencing significantly higher rates compared to developed nations. However, the global incidence is slowly decreasing, albeit at a rate of only about 1.6% per year, insufficient to meet global targets for TB elimination. Among individuals with HIV, TB is the leading cause of death, as HIV-induced CD4 cell depletion impairs the immune response necessary to control M. tuberculosis infection, often leading to disseminated disease.

Beyond HIV, several other factors increase the risk of developing active TB. These include medical conditions like diabetes mellitus, chronic corticosteroid use, and TNF-alpha inhibitor therapy. Gastrectomy has also been identified as a risk factor, possibly due to nutritional deficiencies. Rare genetic defects affecting interferon-gamma, IL-12, and IL-23 signaling pathways can also predispose individuals to more severe TB.

Transmission of M. tuberculosis occurs primarily through airborne microdroplets generated when individuals with active pulmonary TB cough, sneeze, sing, or shout. Prolonged close contact is the main risk factor for transmission, making household members and close contacts of active TB cases particularly vulnerable. Crowded settings like prisons, mines, and public transportation also facilitate TB transmission. Individuals with smear-positive pulmonary TB, indicating a high bacterial load in sputum, are considered highly infectious. Cavitary lung disease is also associated with increased transmission risk, as cavities facilitate the expulsion of bacilli into the airways. Children under 5 years of age and people living with HIV are at increased risk of acquiring TB infection upon exposure.

Pathophysiology of Pulmonary Tuberculosis

Pulmonary tuberculosis is characterized by destructive inflammation and necrosis of lung tissue, distinguishing it from other lung infections that primarily affect the airways. Several virulence factors contribute to the pathogenesis of M. tuberculosis, including mycolic acid glycolipids, lipoarabinomannan (LAM), sulfatides, and trehalose dimycolate found in the bacterial cell wall. These factors play diverse roles in pathogenesis, including evading immune responses, modulating cytokine production, and influencing cellular metabolism. For example, the Mce1A protein is involved in cellular transport and contributes to TB pathogenesis, although its exact mechanism remains under investigation.

The unique cell wall of M. tuberculosis, rich in mycolic acids, is essential for intracellular survival within macrophages. The bacterium also employs various secretion systems, such as ESX-1, Sec, and TAT, to facilitate translocation and interaction with the host environment. Unlike many other pathogenic bacteria that actively attack host tissues or evade defenses, M. tuberculosis primarily focuses on long-term survival within the host. A striking example of this survival strategy is the bacterium’s ability to utilize host cholesterol, a mechanism that enhances its persistence within the human host.

Histopathology of Tuberculosis

The hallmark of tuberculosis histopathology is the formation of granulomas. These are organized aggregates of immune cells, primarily macrophages, surrounded by lymphocytes. A key feature differentiating tuberculous granulomas from those seen in other granulomatous diseases, such as histoplasmosis or leishmaniasis, is the presence of caseation necrosis, or central necrosis. Caseation refers to a cheese-like appearance of the necrotic tissue, resulting from the breakdown of cells and proteins within the granuloma. The presence of caseating granulomas is a strong indicator of tuberculosis, although it is not entirely specific and can be seen in some other conditions.

History and Physical Examination in Tuberculosis

Following primary infection with M. tuberculosis, most individuals remain asymptomatic. In these cases, the infection is either cleared by the immune system or enters a latent phase, with the potential for reactivation later in life. However, approximately 10% of infected individuals, particularly those with weakened immune systems, develop symptomatic primary pulmonary tuberculosis or disseminated disease.

Prolonged fever is the most common symptom of pulmonary TB, while respiratory symptoms are present in only about one-third of patients initially. The fever often exhibits a diurnal pattern, increasing during the day and subsiding at night, and may be accompanied by night sweats. Pulmonary symptoms can include chest pain, shortness of breath, and cough. The cough is often initially mild and non-productive but may progress to produce green or blood-tinged sputum as the disease advances. Non-pulmonary symptoms, such as lymphadenopathy, fatigue, and pharyngitis, can also occur. In advanced cases, patients may experience anorexia, weight loss, and muscle wasting.

Latent tuberculosis infection (LTBI) is a distinctive characteristic of TB. Most infected individuals do not develop immediate symptoms, entering a latent state that can persist for months to years after initial exposure. During latency, the bacteria are thought to be in a non-replicating or slowly replicating state. Reactivation of latent TB is a prolonged process that can take years to manifest clinically. Symptoms of reactivation TB are similar to those of primary disease, including fever, cough, shortness of breath, and weight loss.

Physical examination findings in pulmonary TB can be non-specific, especially in mild cases. Lung auscultation may reveal crackles or tubular breath sounds. Absent breath sounds may be noted over areas of consolidation. Extrapulmonary signs, such as digital clubbing, may be present in chronic cases or those with distant organ involvement.

Evaluation and Diagnostic Approach to Tuberculosis

The diagnostic workup for suspected tuberculosis begins with a chest radiograph (CXR). Evaluation for TB should be initiated in individuals presenting with a cough lasting longer than three weeks, especially when accompanied by systemic symptoms such as fever, night sweats, hemoptysis, or unexplained weight loss. High-risk groups, including HIV-positive individuals, close contacts of active TB cases, individuals from low socioeconomic backgrounds, those with chronic illnesses (diabetes, chronic kidney disease, malignancy, immunosuppression), and intravenous drug users, should also be promptly evaluated for TB in the setting of prolonged or unexplained illness.

If the CXR is suggestive of TB, sputum samples are crucial for microbiological confirmation. Three sputum specimens should be collected for acid-fast bacilli (AFB) smear microscopy and culture. At least one sample should also be tested using nucleic acid amplification tests (NAAT), such as PCR, for rapid detection of M. tuberculosis DNA. Positive AFB smear and NAAT results strongly suggest active TB, and treatment should be initiated promptly. Tuberculin skin test (TST) or interferon-gamma release assays (IGRAs) can be used as adjuncts to support the diagnosis of TB infection. However, it is important to note that negative TST or IGRA results do not exclude active TB disease, particularly in immunocompromised individuals or those with early-stage infection. In cases with non-definitive results, bronchoscopy with bronchoalveolar lavage or lung biopsy may be considered to obtain respiratory samples for further diagnostic evaluation.

Radiological Findings in Pulmonary Tuberculosis

Chest radiography plays a vital role in the initial assessment of suspected pulmonary TB. Early in the disease, CXR findings may be subtle or even normal. Hilar lymphadenopathy is a classic radiological feature of primary TB, particularly in children and young adults. Other common CXR findings include perihilar or right upper lobe infiltrates and pleural effusions. Cavitation, representing lung tissue necrosis, is a hallmark of active pulmonary TB, especially in reactivation disease. However, it’s important to recognize that CXR findings in TB can be variable and may mimic other lung conditions, necessitating a comprehensive differential diagnosis.

Treatment and Management of Tuberculosis

The cornerstone of tuberculosis management is anti-tuberculosis chemotherapy. International guidelines, such as those from the American Thoracic Society (ATS), Centers for Disease Control and Prevention (CDC), and WHO, provide evidence-based recommendations for TB treatment. The primary goals of TB treatment are to eradicate the M. tuberculosis bacteria, prevent relapse, and minimize the development of drug resistance.

Treatment for drug-susceptible TB typically consists of a two-phase regimen: an intensive phase followed by a continuation phase. The standard intensive phase, lasting for two months, involves a four-drug combination: isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), and ethambutol (EMB). The continuation phase, lasting at least four months, usually involves two drugs: isoniazid and rifampin. Directly observed therapy (DOT), where healthcare workers directly observe patients taking their medication, is recommended to enhance adherence and treatment success. Sputum AFB cultures should be monitored monthly during treatment until at least two consecutive samples are negative, indicating treatment response.

The preferred regimen for drug-susceptible TB is 8 weeks of INH, RIF, PZA, and EMB, followed by 18 weeks of INH and RIF. Medications are typically administered daily, seven days a week. In cases where adherence is a concern, intermittent dosing (e.g., three times weekly) may be considered for the continuation phase. Once drug susceptibility testing results are available and confirm susceptibility to INH and RIF, ethambutol may be discontinued in the continuation phase. Pyridoxine (vitamin B6) supplementation is recommended for patients at increased risk of INH-induced neuropathy, such as pregnant women, breastfeeding mothers, infants, individuals with diabetes, chronic kidney disease, alcoholism, older adults, and HIV-positive individuals.

Treatment of TB in HIV-positive patients presents unique challenges due to potential drug interactions with antiretroviral therapy (ART). However, the recommended duration of treatment (two months intensive phase and four months continuation phase) is generally the same for HIV-positive and HIV-negative individuals with drug-susceptible TB. An exception is when patients with HIV are not receiving ART, in which case a longer continuation phase of seven months may be considered. Co-administration of trimethoprim-sulfamethoxazole (TMP-SMX) with anti-TB drugs has been shown to improve outcomes in HIV-positive patients with active TB, particularly those with low CD4 counts (<200 cells/µL).

Latent tuberculosis infection (LTBI) is treated with shorter regimens and fewer medications compared to active TB. Current LTBI treatment guidelines recommend rifamycin-based regimens as preferred options and isoniazid monotherapy as an alternative. A three-month regimen of once-weekly isoniazid plus rifapentine is strongly recommended for adults and children over 2 years of age. Four months of daily rifampin is another preferred regimen for HIV-negative adults and children. Three months of daily isoniazid plus rifampin is conditionally recommended for adults, children, and HIV-infected individuals. Six or nine months of daily isoniazid are alternative regimens.

Adverse drug reactions are a concern with anti-TB medications. Severe side effects requiring treatment discontinuation occur in 4% to 9% of patients. Common side effects include nausea, vomiting, and skin rashes. Hepatotoxicity is a serious concern, occurring in approximately 2.4% of cases. Liver function tests should be monitored regularly, and treatment may need to be temporarily interrupted if liver enzymes rise significantly. Ethambutol can cause optic neuritis, and baseline and follow-up ophthalmologic examinations are recommended. Isoniazid can cause peripheral neuropathy, which can be mitigated with pyridoxine supplementation.

Drug-Resistant Tuberculosis

Drug resistance is a major global challenge in TB control. Multidrug-resistant TB (MDR-TB), defined as resistance to both isoniazid and rifampin, poses significant treatment difficulties. The prevalence of MDR-TB varies geographically, with higher rates in high-TB burden countries. Drug-resistant TB is classified into different categories:

• Mono-resistant TB: Resistance to only one first-line anti-TB drug.
• Polydrug-resistant TB: Resistance to more than one first-line drug, but not both isoniazid and rifampin.
• Multidrug-resistant TB (MDR-TB): Resistance to at least isoniazid and rifampin.
• Extensively drug-resistant TB (XDR-TB): MDR-TB with additional resistance to a fluoroquinolone and at least one injectable second-line drug.

Drug resistance can develop due to various factors, including inadequate treatment regimens, medication shortages, poor patient adherence, and transmission of drug-resistant strains. Drug susceptibility testing (DST) is essential to diagnose drug-resistant TB. Molecular DST methods are increasingly available, allowing for rapid detection of mutations associated with drug resistance.

Treatment of MDR-TB is complex, prolonged, and less effective than treatment for drug-susceptible TB. Second-line anti-TB drugs are used, often in combination regimens lasting 20 months or longer. A typical MDR-TB regimen includes four or more drugs, including an injectable agent (e.g., kanamycin, capreomycin), a fluoroquinolone (e.g., moxifloxacin, levofloxacin), and other second-line agents. Treatment outcomes for MDR-TB are significantly worse, with global cure rates ranging from 20% to 48% in some surveys.

Differential Diagnosis of Tuberculosis

Pulmonary tuberculosis shares clinical and radiological features with a wide range of other lung diseases. A thorough differential diagnosis is crucial to ensure accurate diagnosis and appropriate management. The differential diagnosis of tuberculosis includes:

1. Sarcoidosis: Sarcoidosis is a systemic granulomatous disease of unknown etiology that commonly affects the lungs. Like TB, sarcoidosis can present with pulmonary infiltrates, hilar lymphadenopathy, and granulomas on histology. However, sarcoid granulomas are typically non-caseating, unlike the caseating granulomas of TB. Clinical features that favor sarcoidosis over TB include bilateral hilar lymphadenopathy, skin lesions (erythema nodosum, lupus pernio), uveitis, and lack of systemic symptoms like fever and night sweats. Bronchoalveolar lavage in sarcoidosis often shows lymphocytosis, while TB typically shows a mixed cellular pattern. Ultimately, tissue biopsy with demonstration of non-caseating granulomas and negative stains and cultures for mycobacteria and fungi are necessary to differentiate sarcoidosis from TB definitively.

   Alt Text: Chest X-ray illustrating stage 2 sarcoidosis, characterized by bilateral hilar lymphadenopathy.

2. Fungal Infections: Various fungal infections can mimic pulmonary tuberculosis, particularly in endemic areas or in immunocompromised individuals. These include:

   • Histoplasmosis: Caused by Histoplasma capsulatum, histoplasmosis is endemic in certain regions, particularly the Ohio and Mississippi River valleys in the United States. Pulmonary histoplasmosis can present with fever, cough, and pulmonary infiltrates, similar to TB. Radiologically, histoplasmosis may show hilar lymphadenopathy and granulomas. Histoplasmosis granulomas, however, are typically non-caseating or have less prominent caseation than TB granulomas. Epidemiological history (travel to endemic areas), skin testing, serology, and urine antigen testing can aid in the diagnosis of histoplasmosis. Culture of sputum or bronchoalveolar lavage fluid can confirm the diagnosis.

   • Aspergillosis: Aspergillus species, particularly Aspergillus fumigatus, can cause various pulmonary syndromes, including allergic bronchopulmonary aspergillosis (ABPA), aspergilloma, and invasive aspergillosis. Invasive aspergillosis, seen primarily in immunocompromised patients, can present with fever, cough, hemoptysis, and pulmonary infiltrates that can resemble TB. However, invasive aspergillosis typically progresses more rapidly than TB. Aspergillomas, or fungal balls, can develop in pre-existing lung cavities, including those caused by prior TB. Diagnosis of aspergillosis involves fungal cultures, galactomannan antigen testing, and imaging findings such as the air crescent sign in aspergilloma.

   • Actinomycosis and Nocardiosis: These bacterial infections, caused by Actinomyces and Nocardia species, respectively, are filamentous bacteria that can mimic TB. Pulmonary actinomycosis often presents with chronic, indolent infection, sometimes with chest wall involvement and draining sinuses. Nocardiosis can cause pulmonary infiltrates, nodules, and cavitation, resembling TB. Gram stain and modified acid-fast stain can help differentiate these infections from TB. Culture is essential for definitive diagnosis.

   • Blastomycosis and Coccidioidomycosis: These systemic mycoses, caused by Blastomyces dermatitidis and Coccidioides immitis, respectively, are geographically restricted fungal infections. Blastomycosis is endemic to the southeastern and central United States, while coccidioidomycosis is endemic to the southwestern United States and parts of Latin America. Both infections can cause pulmonary symptoms and radiographic findings that overlap with TB, including nodules, infiltrates, and cavities. Epidemiological history, skin testing, serology, and culture can help distinguish these fungal infections from TB.

3. Nontuberculous Mycobacterial (NTM) Infections: NTM, also known as mycobacteria other than tuberculosis (MOTT), are mycobacterial species other than M. tuberculosis complex. Mycobacterium avium complex (MAC) and Mycobacterium kansasii are the most common NTM species causing pulmonary disease. NTM pulmonary infections can clinically and radiologically resemble TB, presenting with chronic cough, sputum production, and apical pulmonary infiltrates or cavities, particularly in individuals with underlying lung disease. However, NTM infections are generally less contagious than TB and may have different treatment regimens. Definitive diagnosis requires isolation and identification of NTM species from respiratory specimens and exclusion of M. tuberculosis.

4. Lung Malignancy and Lymphoma: Lung cancer and lymphoma can present with pulmonary masses, nodules, or infiltrates that may be mistaken for tuberculosis, particularly in older adults or smokers. Lung cancer may present with cough, hemoptysis, and weight loss, similar to TB. Lymphoma can also involve the lungs and mediastinal lymph nodes, mimicking TB lymphadenopathy. Features suggestive of malignancy include solitary pulmonary nodule, mass lesion, absence of systemic symptoms, and lack of response to anti-TB therapy. Tissue biopsy, either bronchoscopic or surgical, is often necessary to rule out malignancy in suspected cases of TB, especially if atypical features are present or if there is no clinical improvement with TB treatment.

5. Lung Abscess: Lung abscess is a localized collection of pus within the lung parenchyma, often resulting from bacterial pneumonia, aspiration, or bronchial obstruction. Lung abscess can present with fever, cough, sputum production, and chest pain, which may overlap with TB. Radiologically, lung abscess appears as a cavitary lesion with an air-fluid level, which can resemble a TB cavity. However, lung abscesses typically have a more acute presentation, often associated with a history of pneumonia or aspiration risk factors. Sputum Gram stain and culture are helpful in diagnosing lung abscess and identifying the causative bacteria. While TB cavities can also develop air-fluid levels, the clinical context and microbiological findings help differentiate lung abscess from TB.

Treatment Planning and Monitoring in Tuberculosis

Patients diagnosed with active tuberculosis require careful treatment planning and ongoing monitoring. Sputum smear microscopy and culture, along with drug susceptibility testing, should be repeated at 2-3 month intervals during treatment to assess treatment response and detect drug resistance. A sputum sample should also be obtained at the end of treatment to confirm bacteriological cure. Chest radiography or other imaging modalities should be repeated at approximately two months after treatment initiation and at the end of therapy to monitor radiographic improvement. For patients receiving ethambutol, visual acuity and color vision should be assessed at baseline and periodically during treatment to monitor for optic neuritis. Baseline screening for hepatitis B and C is recommended for patients at risk, such as intravenous drug users. Monthly laboratory monitoring, including complete blood count, liver enzymes, and creatinine, should be initiated after one month of anti-TB therapy to detect drug-induced toxicities. For HIV-positive patients, CD4 cell count and HIV viral load should be monitored regularly during TB treatment and ART.

Prognosis of Tuberculosis

The prognosis of tuberculosis is variable and depends on several factors, including patient age, immune status, comorbidities, time of diagnosis and treatment initiation, drug susceptibility, and treatment adherence. In general, with prompt diagnosis and appropriate treatment, drug-susceptible pulmonary tuberculosis has a good prognosis, with treatment success rates around 85%. However, the World Health Organization estimates the global mortality rate for TB to be approximately 15%, highlighting the significant global burden of this disease. Factors associated with poorer prognosis include advanced age, HIV co-infection, drug resistance, extensive lung disease, and delayed treatment.

Complications of Pulmonary Tuberculosis

Pulmonary tuberculosis can lead to various complications, both pulmonary and extrapulmonary. Pulmonary complications include:

• Hemoptysis: Bleeding from bronchial or pulmonary arteries can occur due to erosion of blood vessels within tuberculous cavities or inflamed lung tissue. Hemoptysis is usually mild but can occasionally be massive and life-threatening.

• Pneumothorax: Rupture of a subpleural tuberculous focus or lung cavity into the pleural space can cause spontaneous pneumothorax.

• Bronchiectasis: Lymph node enlargement and inflammation can compress bronchi, leading to bronchial damage and bronchiectasis, a chronic condition characterized by irreversible bronchial dilation.

• Extensive Lung Destruction and Gangrene: Severe, untreated pulmonary TB can result in extensive lung destruction, necrosis, and even pulmonary gangrene.

• Increased Risk of Lung Cancer: Chronic pulmonary tuberculosis has been reported to increase the risk of developing lung cancer in the affected lung.

• Chronic Pulmonary Aspergillosis: Pre-existing TB cavities can be colonized by Aspergillus fungi, leading to chronic pulmonary aspergillosis.

• Septic Shock: In rare cases, severe tuberculosis can progress to septic shock, a life-threatening condition characterized by systemic inflammation and organ dysfunction.

Deterrence and Patient Education for Tuberculosis

Effective tuberculosis prevention strategies are crucial for global TB control. The most effective approach to prevent TB disease is early case detection and prompt treatment of active TB cases. Effective treatment significantly reduces the bacterial load and transmission within communities. The Bacillus Calmette-Guérin (BCG) vaccine is available for TB prevention and is widely used globally, particularly in high-burden countries. BCG is typically administered at birth or in infancy and has been shown to reduce the risk of severe childhood TB, such as tuberculous meningitis and disseminated TB. However, BCG vaccine efficacy against adult pulmonary TB is variable and limited.

The “FAST” approach (Find cases Actively through rapid molecular testing, Separate infectious patients safely, and initiate appropriate Treatment) is an effective strategy to reduce nosocomial TB transmission in healthcare settings. Identifying and mapping TB “hot spots” within geographical areas and providing targeted preventive therapy, such as isoniazid preventive therapy (IPT) for latent TB infection, can reduce disease burden in communities. Socioeconomic development, including improving living conditions, reducing overcrowding, and enhancing nutritional status, plays a crucial role in reducing TB transmission and incidence.

Several new TB vaccine candidates are under development, showing promising results in animal models. However, none have yet demonstrated superior efficacy to BCG in humans. Clinical trials are ongoing to evaluate the safety and efficacy of these new TB vaccines.

Patient education is essential for successful TB treatment and prevention. Patients need to be educated about TB disease, treatment objectives, medications, potential side effects, and infection control measures. Healthcare educators and pharmacists play a vital role in providing comprehensive patient education and counseling to improve treatment adherence and outcomes.

Enhancing Healthcare Team Outcomes in Tuberculosis Management

Effective tuberculosis management requires a collaborative, interprofessional healthcare team approach. National TB programs play a crucial role in coordinating TB control efforts, including case detection, sample processing, and treatment monitoring. Infection control measures in healthcare facilities and communities are essential to prevent TB transmission. Directly observed therapy (DOT) requires coordinated efforts from healthcare providers, case managers, and community health workers to ensure treatment adherence. Effective communication between patients, healthcare providers, and public health agencies is vital for successful TB control. Clinical pharmacists play a key role in optimizing drug regimens, managing drug interactions, and minimizing adverse drug reactions, particularly in the management of drug-resistant TB. A cohesive, collaborative interprofessional team is essential to optimize patient outcomes and achieve global TB control goals.

Review Questions

(Note: Review questions are present in the original article but are not requested for inclusion in the rewritten article based on instructions.)

References

(The original reference list is comprehensive and relevant. It should be retained in the new article to maintain credibility and facilitate further reading for users.)

1.Churchyard G, Kim P, Shah NS, Rustomjee R, Gandhi N, Mathema B, Dowdy D, Kasmar A, Cardenas V. What We Know About Tuberculosis Transmission: An Overview. J Infect Dis. 2017 Nov 03;216(suppl_6):S629-S635. [PMC free article: PMC5791742] [PubMed: 29112747]

2.Barbier M, Wirth T. The Evolutionary History, Demography, and Spread of the Mycobacterium tuberculosis Complex. Microbiol Spectr. 2016 Aug;4(4) [PubMed: 27726798]

3.Furin J, Cox H, Pai M. Tuberculosis. Lancet. 2019 Apr 20;393(10181):1642-1656. [PubMed: 30904262]

4.Sudarsan TI, Thomas L, Samprathi A, Chacko B, Mathuram A, George T, Karthik G, Rajan SJ, Carey RAB, Mahasampath G, Peter JV. Tuberculous ARDS is associated with worse outcome when compared with non-tuberculous infectious ARDS. J Crit Care. 2021 Feb;61:138-143. [PubMed: 33161242]

5.Houben RM, Dodd PJ. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLoS Med. 2016 Oct;13(10):e1002152. [PMC free article: PMC5079585] [PubMed: 27780211]

6.Comas I, Coscolla M, Luo T, Borrell S, Holt KE, Kato-Maeda M, Parkhill J, Malla B, Berg S, Thwaites G, Yeboah-Manu D, Bothamley G, Mei J, Wei L, Bentley S, Harris SR, Niemann S, Diel R, Aseffa A, Gao Q, Young D, Gagneux S. Out-of-Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern humans. Nat Genet. 2013 Oct;45(10):1176-82. [PMC free article: PMC3800747] [PubMed: 23995134]

7.Farer LS, Lowell AM, Meador MP. Extrapulmonary tuberculosis in the United States. Am J Epidemiol. 1979 Feb;109(2):205-17. [PubMed: 425959]

8.Comstock GW. Epidemiology of tuberculosis. Am Rev Respir Dis. 1982 Mar;125(3 Pt 2):8-15. [PubMed: 7073104]

9.Dheda K, Barry CE, Maartens G. Tuberculosis. Lancet. 2016 Mar 19;387(10024):1211-26. [PMC free article: PMC11268880] [PubMed: 26377143]

10.Hagan G, Nathani N. Clinical review: tuberculosis on the intensive care unit. Crit Care. 2013 Sep 27;17(5):240. [PMC free article: PMC4056111] [PubMed: 24093433]

11.Guirado E, Schlesinger LS. Modeling the Mycobacterium tuberculosis Granuloma – the Critical Battlefield in Host Immunity and Disease. Front Immunol. 2013;4:98. [PMC free article: PMC3631743] [PubMed: 23626591]

12.Bañuls AL, Sanou A, Van Anh NT, Godreuil S. Mycobacterium tuberculosis: ecology and evolution of a human bacterium. J Med Microbiol. 2015 Nov;64(11):1261-1269. [PubMed: 26385049]

13.Fedrizzi T, Meehan CJ, Grottola A, Giacobazzi E, Fregni Serpini G, Tagliazucchi S, Fabio A, Bettua C, Bertorelli R, De Sanctis V, Rumpianesi F, Pecorari M, Jousson O, Tortoli E, Segata N. Genomic characterization of Nontuberculous Mycobacteria. Sci Rep. 2017 Mar 27;7:45258. [PMC free article: PMC5366915] [PubMed: 28345639]

14.Cousins DV, Bastida R, Cataldi A, Quse V, Redrobe S, Dow S, Duignan P, Murray A, Dupont C, Ahmed N, Collins DM, Butler WR, Dawson D, Rodríguez D, Loureiro J, Romano MI, Alito A, Zumarraga M, Bernardelli A. Tuberculosis in seals caused by a novel member of the Mycobacterium tuberculosis complex: Mycobacterium pinnipedii sp. nov. Int J Syst Evol Microbiol. 2003 Sep;53(Pt 5):1305-1314. [PubMed: 13130011]

15.Converse SE, Mougous JD, Leavell MD, Leary JA, Bertozzi CR, Cox JS. MmpL8 is required for sulfolipid-1 biosynthesis and Mycobacterium tuberculosis virulence. Proc Natl Acad Sci U S A. 2003 May 13;100(10):6121-6. [PMC free article: PMC156336] [PubMed: 12724526]

16.Jasmer RM, Nahid P, Hopewell PC. Clinical practice. Latent tuberculosis infection. N Engl J Med. 2002 Dec 05;347(23):1860-6. [PubMed: 12466511]

17.Allen BW, Mitchison DA. Counts of viable tubercle bacilli in sputum related to smear and culture gradings. Med Lab Sci. 1992 Jun;49(2):94-8. [PubMed: 1487984]

18.Kwan CK, Ernst JD. HIV and tuberculosis: a deadly human syndemic. Clin Microbiol Rev. 2011 Apr;24(2):351-76. [PMC free article: PMC3122491] [PubMed: 21482729]

19.GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016 Oct 08;388(10053):1459-1544. [PMC free article: PMC5388903] [PubMed: 27733281]

20.Fogel N. Tuberculosis: a disease without boundaries. Tuberculosis (Edinb). 2015 Sep;95(5):527-31. [PubMed: 26198113]

21.Zaheen A, Bloom BR. Tuberculosis in 2020 – New Approaches to a Continuing Global Health Crisis. N Engl J Med. 2020 Apr 02;382(14):e26. [PubMed: 32242354]

22.GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1789-1858. [PMC free article: PMC6227754] [PubMed: 30496104]

23.Tiberi S, Carvalho AC, Sulis G, Vaghela D, Rendon A, Mello FC, Rahman A, Matin N, Zumla A, Pontali E. The cursed duet today: Tuberculosis and HIV-coinfection. Presse Med. 2017 Mar;46(2 Pt 2):e23-e39. [PubMed: 28256380]

24.Khan K, Wang J, Hu W, Bierman A, Li Y, Gardam M. Tuberculosis infection in the United States: national trends over three decades. Am J Respir Crit Care Med. 2008 Feb 15;177(4):455-60. [PubMed: 18029790]

25.Cheng KC, Liao KF, Lin CL, Lai SW. Gastrectomy correlates with increased risk of pulmonary tuberculosis: A population-based cohort study in Taiwan. Medicine (Baltimore). 2018 Jul;97(27):e11388. [PMC free article: PMC6076070] [PubMed: 29979430]

26.Boisson-Dupuis S, Bustamante J, El-Baghdadi J, Camcioglu Y, Parvaneh N, El Azbaoui S, Agader A, Hassani A, El Hafidi N, Mrani NA, Jouhadi Z, Ailal F, Najib J, Reisli I, Zamani A, Yosunkaya S, Gulle-Girit S, Yildiran A, Cipe FE, Torun SH, Metin A, Atikan BY, Hatipoglu N, Aydogmus C, Kilic SS, Dogu F, Karaca N, Aksu G, Kutukculer N, Keser-Emiroglu M, Somer A, Tanir G, Aytekin C, Adimi P, Mahdaviani SA, Mamishi S, Bousfiha A, Sanal O, Mansouri D, Casanova JL, Abel L. Inherited and acquired immunodeficiencies underlying tuberculosis in childhood. Immunol Rev. 2015 Mar;264(1):103-20. [PMC free article: PMC4405179] [PubMed: 25703555]

27.Turner RD, Bothamley GH. Cough and the transmission of tuberculosis. J Infect Dis. 2015 May 01;211(9):1367-72. [PubMed: 25387581]

28.Kurtuluş Ş, Can R, Sak ZHA. New perspective on rise of tuberculosis cases: communal living. Cent Eur J Public Health. 2020 Dec;28(4):302-305. [PubMed: 33338367]

29.Hanifa Y, Grant AD, Lewis J, Corbett EL, Fielding K, Churchyard G. Prevalence of latent tuberculosis infection among gold miners in South Africa. Int J Tuberc Lung Dis. 2009 Jan;13(1):39-46. [PubMed: 19105877]

30.Andrews JR, Morrow C, Walensky RP, Wood R. Integrating social contact and environmental data in evaluating tuberculosis transmission in a South African township. J Infect Dis. 2014 Aug 15;210(4):597-603. [PMC free article: PMC4133578] [PubMed: 24610874]

31.Zelner JL, Murray MB, Becerra MC, Galea J, Lecca L, Calderon R, Yataco R, Contreras C, Zhang Z, Grenfell BT, Cohen T. Age-specific risks of tuberculosis infection from household and community exposures and opportunities for interventions in a high-burden setting. Am J Epidemiol. 2014 Oct 15;180(8):853-61. [PMC free article: PMC4188339] [PubMed: 25190676]

32.Kaplan G, Post FA, Moreira AL, Wainwright H, Kreiswirth BN, Tanverdi M, Mathema B, Ramaswamy SV, Walther G, Steyn LM, Barry CE, Bekker LG. Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun. 2003 Dec;71(12):7099-108. [PMC free article: PMC308931] [PubMed: 14638800]

33.Martinez L, Cords O, Horsburgh CR, Andrews JR., Pediatric TB Contact Studies Consortium. The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis. Lancet. 2020 Mar 21;395(10228):973-984. [PMC free article: PMC7289654] [PubMed: 32199484]

34.Elkington P, Lerm M, Kapoor N, Mahon R, Pienaar E, Huh D, Kaushal D, Schlesinger LS. In Vitro Granuloma Models of Tuberculosis: Potential and Challenges. J Infect Dis. 2019 May 24;219(12):1858-1866. [PMC free article: PMC6534193] [PubMed: 30929010]

35.Rastogi N, David HL. Mechanisms of pathogenicity in mycobacteria. Biochimie. 1988 Aug;70(8):1101-20. [PubMed: 3147701]

36.Smith I. Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clin Microbiol Rev. 2003 Jul;16(3):463-96. [PMC free article: PMC164219] [PubMed: 12857778]

37.Casali N, Riley LW. A phylogenomic analysis of the Actinomycetales mce operons. BMC Genomics. 2007 Feb 26;8:60. [PMC free article: PMC1810536] [PubMed: 17324287]

38.Rao V, Fujiwara N, Porcelli SA, Glickman MS. Mycobacterium tuberculosis controls host innate immune activation through cyclopropane modification of a glycolipid effector molecule. J Exp Med. 2005 Feb 21;201(4):535-43. [PMC free article: PMC2213067] [PubMed: 15710652]

39.Voulhoux R, Ball G, Ize B, Vasil ML, Lazdunski A, Wu LF, Filloux A. Involvement of the twin-arginine translocation system in protein secretion via the type II pathway. EMBO J. 2001 Dec 03;20(23):6735-41. [PMC free article: PMC125745] [PubMed: 11726509]

40.Pandey AK, Sassetti CM. Mycobacterial persistence requires the utilization of host cholesterol. Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4376-80. [PMC free article: PMC2393810] [PubMed: 18334639]

41.Milburn HJ. Primary tuberculosis. Curr Opin Pulm Med. 2001 May;7(3):133-41. [PubMed: 11371768]

42.Stead WW, Kerby GR, Schlueter DP, Jordahl CW. The clinical spectrum of primary tuberculosis in adults. Confusion with reinfection in the pathogenesis of chronic tuberculosis. Ann Intern Med. 1968 Apr;68(4):731-45. [PubMed: 5642961]

43.POULSEN A. Some clinical features of tuberculosis. Acta Tuberc Scand. 1957;33(1-2):37-92; concl. [PubMed: 13424392]

44.Long B, Liang SY, Koyfman A, Gottlieb M. Tuberculosis: a focused review for the emergency medicine clinician. Am J Emerg Med. 2020 May;38(5):1014-1022. [PubMed: 31902701]

45.Schlossberg D. Acute tuberculosis. Infect Dis Clin North Am. 2010 Mar;24(1):139-46. [PubMed: 20171549]

46.Barry CE, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, Schnappinger D, Wilkinson RJ, Young D. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol. 2009 Dec;7(12):845-55. [PMC free article: PMC4144869] [PubMed: 19855401]

47.Gill WP, Harik NS, Whiddon MR, Liao RP, Mittler JE, Sherman DR. A replication clock for Mycobacterium tuberculosis. Nat Med. 2009 Feb;15(2):211-4. [PMC free article: PMC2779834] [PubMed: 19182798]

48.MacGregor RR. A year’s experience with tuberculosis in a private urban teaching hospital in the postsanatorium era. Am J Med. 1975 Feb;58(2):221-8. [PubMed: 1115069]

49.Miller LG, Asch SM, Yu EI, Knowles L, Gelberg L, Davidson P. A population-based survey of tuberculosis symptoms: how atypical are atypical presentations? Clin Infect Dis. 2000 Feb;30(2):293-9. [PubMed: 10671331]

50.Sgaragli G, Frosini M. Human Tuberculosis I. Epidemiology, Diagnosis and Pathogenetic Mechanisms. Curr Med Chem. 2016;23(25):2836-2873. [PubMed: 27281297]

51.Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, Keane J, Lewinsohn DA, Loeffler AM, Mazurek GH, O’Brien RJ, Pai M, Richeldi L, Salfinger M, Shinnick TM, Sterling TR, Warshauer DM, Woods GL. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis. 2017 Jan 15;64(2):e1-e33. [PubMed: 27932390]

52.Malekmohammad M, Marjani M, Tabarsi P, Baghaei P, Sadr Z, Naghan PA, Mansouri D, Masjedi MR, Velayati AA. Diagnostic yield of post-bronchoscopy sputum smear in pulmonary tuberculosis. Scand J Infect Dis. 2012 May;44(5):369-73. [PubMed: 22497518]

53.Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH, Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA, Lienhardt C, Menzies R, Merrifield C, Narita M, O’Brien R, Peloquin CA, Raftery A, Saukkonen J, Schaaf HS, Sotgiu G, Starke JR, Migliori GB, Vernon A. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016 Oct 01;63(7):e147-e195. [PMC free article: PMC6590850] [PubMed: 27516382]

54.Johnson JL, Hadad DJ, Dietze R, Maciel EL, Sewali B, Gitta P, Okwera A, Mugerwa RD, Alcaneses MR, Quelapio MI, Tupasi TE, Horter L, Debanne SM, Eisenach KD, Boom WH. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med. 2009 Sep 15;180(6):558-63. [PMC free article: PMC2742745] [PubMed: 19542476]

55.Small PM, Fujiwara PI. Management of tuberculosis in the United States. N Engl J Med. 2001 Jul 19;345(3):189-200. [PubMed: 11463015]

56.Chaulk CP, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis: Consensus Statement of the Public Health Tuberculosis Guidelines Panel. JAMA. 1998 Mar 25;279(12):943-8. [PubMed: 9544769]

57.LoBue PA, Moser KS. Isoniazid- and rifampin-resistant tuberculosis in San Diego County, California, United States, 1993-2002. Int J Tuberc Lung Dis. 2005 May;9(5):501-6. [PubMed: 15875920]

58.Snider DE. Pyridoxine supplementation during isoniazid therapy. Tubercle. 1980 Dec;61(4):191-6. [PubMed: 6269259]

59.Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet. 1999 May 29;353(9167):1843-7. [PubMed: 10359410]

60.Masur H, Brooks JT, Benson CA, Holmes KK, Pau AK, Kaplan JE., National Institutes of Health. Centers for Disease Control and Prevention. HIV Medicine Association of the Infectious Diseases Society of America. Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Updated Guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014 May;58(9):1308-11. [PMC free article: PMC3982842] [PubMed: 24585567]

61.Gülbay BE, Gürkan OU, Yildiz OA, Onen ZP, Erkekol FO, Baççioğlu A, Acican T. Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. Respir Med. 2006 Oct;100(10):1834-42. [PubMed: 16517138]

62.Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003 Jun 01;167(11):1472-7. [PubMed: 12569078]

63.Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest. 1991 Feb;99(2):465-71. [PubMed: 1824929]

64.Schaberg T, Bauer T, Brinkmann F, Diel R, Feiterna-Sperling C, Haas W, Hartmann P, Hauer B, Heyckendorf J, Lange C, Nienhaus A, Otto-Knapp R, Priwitzer M, Richter E, Rumetshofer R, Schenkel K, Schoch OD, Schönfeld N, Stahlmann R. [Tuberculosis Guideline for Adults – Guideline for Diagnosis and Treatment of Tuberculosis including LTBI Testing and Treatment of the German Central Committee (DZK) and the German Respiratory Society (DGP)]. Pneumologie. 2017 Jun;71(6):325-397. [PubMed: 28651293]

65.Seung KJ, Keshavjee S, Rich ML. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. Cold Spring Harb Perspect Med. 2015 Apr 27;5(9):a017863. [PMC free article: PMC4561400] [PubMed: 25918181]

66.Zhao Y, Xu S, Wang L, Chin DP, Wang S, Jiang G, Xia H, Zhou Y, Li Q, Ou X, Pang Y, Song Y, Zhao B, Zhang H, He G, Guo J, Wang Y. National survey of drug-resistant tuberculosis in China. N Engl J Med. 2012 Jun 07;366(23):2161-70. [PubMed: 22670902]

67.Falzon D, Jaramillo E, Schünemann HJ, Arentz M, Bauer M, Bayona J, Blanc L, Caminero JA, Daley CL, Duncombe C, Fitzpatrick C, Gebhard A, Getahun H, Henkens M, Holtz TH, Keravec J, Keshavjee S, Khan AJ, Kulier R, Leimane V, Lienhardt C, Lu C, Mariandyshev A, Migliori GB, Mirzayev F, Mitnick CD, Nunn P, Nwagboniwe G, Oxlade O, Palmero D, Pavlinac P, Quelapio MI, Raviglione MC, Rich ML, Royce S, Rüsch-Gerdes S, Salakaia A, Sarin R, Sculier D, Varaine F, Vitoria M, Walson JL, Wares F, Weyer K, White RA, Zignol M. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J. 2011 Sep;38(3):516-28. [PubMed: 21828024]

68.Lin H, Shin S, Blaya JA, Zhang Z, Cegielski P, Contreras C, Asencios L, Bonilla C, Bayona J, Paciorek CJ, Cohen T. Assessing spatiotemporal patterns of multidrug-resistant and drug-sensitive tuberculosis in a South American setting. Epidemiol Infect. 2011 Nov;139(11):1784-93. [PMC free article: PMC3153578] [PubMed: 21205434]

69.Iketleng T, Lessells R, Dlamini MT, Mogashoa T, Mupfumi L, Moyo S, Gaseitsiwe S, de Oliveira T. Mycobacterium tuberculosis Next-Generation Whole Genome Sequencing: Opportunities and Challenges. Tuberc Res Treat. 2018;2018:1298542. [PMC free article: PMC6304523] [PubMed: 30631597]

70.Wells CD, Cegielski JP, Nelson LJ, Laserson KF, Holtz TH, Finlay A, Castro KG, Weyer K. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis. 2007 Aug 15;196 Suppl 1:S86-107. [PubMed: 17624830]

71.THOMPSON JR. Mechanisms of fatal pulmonary hemorrhage in tuberculosis. Am J Surg. 1955 Mar;89(3):637-44. [PubMed: 13228824]

72.WILDER RJ, BEACHAM EG, RAVITCH MM. Spontaneous pneumothorax complicating cavitary tuberculosis. J Thorac Cardiovasc Surg. 1962 May;43:561-73. [PubMed: 14006972]

73.Rosenzweig DY, Stead WW. The role of tuberculosis and other forms of bronchopulmonary necrosis in the pathogenesis of bronchiectasis. Am Rev Respir Dis. 1966 May;93(5):769-85. [PubMed: 5296012]

74.Khan FA, Rehman M, Marcus P, Azueta V. Pulmonary gangrene occurring as a complication of pulmonary tuberculosis. Chest. 1980 Jan;77(1):76-80. [PubMed: 7351153]

75.Brenner AV, Wang Z, Kleinerman RA, Wang L, Zhang S, Metayer C, Chen K, Lei S, Cui H, Lubin JH. Previous pulmonary diseases and risk of lung cancer in Gansu Province, China. Int J Epidemiol. 2001 Feb;30(1):118-24. [PubMed: 11171871]

76.Page ID, Byanyima R, Hosmane S, Onyachi N, Opira C, Richardson M, Sawyer R, Sharman A, Denning DW. Chronic pulmonary aspergillosis commonly complicates treated pulmonary tuberculosis with residual cavitation. Eur Respir J. 2019 Mar;53(3) [PMC free article: PMC6422837] [PubMed: 30705126]

77.Kethireddy S, Light RB, Mirzanejad Y, Maki D, Arabi Y, Lapinsky S, Simon D, Kumar A, Parrillo JE, Kumar A., Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Group. Mycobacterium tuberculosis septic shock. Chest. 2013 Aug;144(2):474-482. [PubMed: 23429859]

78.Baily GV. Tuberculosis prevention Trial, Madras. Indian J Med Res. 1980 Jul;72 Suppl:1-74. [PubMed: 7005086]

79.Barrera E, Livchits V, Nardell E. F-A-S-T: a refocused, intensified, administrative tuberculosis transmission control strategy. Int J Tuberc Lung Dis. 2015 Apr;19(4):381-4. [PubMed: 25859991]

80.Cegielski JP, Griffith DE, McGaha PK, Wolfgang M, Robinson CB, Clark PA, Hassell WL, Robison VA, Walker KP, Wallace C. Eliminating tuberculosis one neighborhood at a time. Am J Public Health. 2013 Jul;103(7):1292-300. [PMC free article: PMC3682594] [PubMed: 23078465]

81.Dowdy DW, Azman AS, Kendall EA, Mathema B. Transforming the fight against tuberculosis: targeting catalysts of transmission. Clin Infect Dis. 2014 Oct 15;59(8):1123-9. [PMC free article: PMC4481585] [PubMed: 24982034]

82.Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, Shea JE, McClain JB, Hussey GD, Hanekom WA, Mahomed H, McShane H., MVA85A 020 Trial Study Team. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet. 2013 Mar 23;381(9871):1021-8. [PMC free article: PMC5424647] [PubMed: 23391465]

83.Hopewell PC, Pai M, Maher D, Uplekar M, Raviglione MC. International standards for tuberculosis care. Lancet Infect Dis. 2006 Nov;6(11):710-25. [PubMed: 17067920]

84.M’imunya JM, Kredo T, Volmink J. Patient education and counselling for promoting adherence to treatment for tuberculosis. Cochrane Database Syst Rev. 2012 May 16;2012(5):CD006591. [PMC free article: PMC6532681] [PubMed: 22592714]